GlassScriptPhysician profile
Assad Oskuei
NPI 1528313210
$131,851.12
in general payments reported to CMS, 2019-2025
39 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $841 · 2021: $1,648 · 2022: $1,740 · 2023: $2,596 · 2024: $32K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Consulting Fee: $13K · Food and Beverage: $11K · Travel and Lodging: $6,872 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,375.00 |
| Consulting Fee | $12,785.50 |
| Food and Beverage | $10,510.86 |
| Travel and Lodging | $6,871.58 |
| Education | $296.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $78,888.35 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $43,324.86 | 2019-2025 | |
| Medtronic, INC. | $1,648.78 | 2024 | Illumisite |
| Glaxosmithkline, LLC. | $1,472.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $963.54 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Novartis Pharmaceuticals Corporation | $538.86 | 2020-2024 | |
| Genentech USA, INC. | $498.20 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $471.57 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $449.61 | 2021-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $438.35 | 2019-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $390.69 | 2020-2025 | Glassia, Cuvitru |
| Mallinckrodt Hospital Products INC. | $343.81 | 2020-2025 | Acthar |
| Pfizer INC. | $317.52 | 2020-2025 | |
| Amgen INC. | $290.54 | 2022-2024 | Tezspire |
| Amneal Pharmaceuticals LLC | $235.00 | 2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $213.56 | 2020-2024 | (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $156.70 | 2019-2025 | Dupixent |
| United Therapeutics Corporation | $137.52 | 2023-2024 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $97.99 | 2025 | |
| Baxter Healthcare | $96.43 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Alexion Pharmaceuticals, INC. | $92.57 | 2019-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $90.06 | 2020-2022 | |
| Insmed, INC. | $82.16 | 2019-2023 | Arikayce |
| Ani Pharmaceuticals, INC. | $62.43 | 2025 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $60.43 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $55.76 | 2021-2024 | Zerbaxa |
| Advanced Respiratory, INC | $54.85 | 2019-2021 | |
| Covis Pharma Gmbh | $50.34 | 2021-2022 | |
| Abbvie INC. | $49.98 | 2023-2024 | |
| Electromed, INC. | $49.69 | 2023-2025 | Smartvest |
| Inogen, INC. | $39.64 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sunovion Pharmaceuticals INC. | $38.77 | 2021 | |
| Sanofi Pasteur INC. | $29.12 | 2023-2024 | |
| Inspire Medical Systems, INC. | $28.17 | 2023 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $23.28 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.76 | 2024 | Eliquis |
| Boston Scientific Corporation | $18.98 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.45 | 2022 | |
| Bio Products Laboratory USA, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Assad Oskuei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.